期刊
EXPERIMENTAL HEMATOLOGY
卷 43, 期 9, 页码 770-774出版社
ELSEVIER SCIENCE INC
DOI: 10.1016/j.exphem.2015.04.008
关键词
-
资金
- Leukemia and Lymphoma Society [7004-11]
- Harry Mangurian Foundation
- D. Warren Brown Foundation
- Robert I Anthony Leukemia Fund
- National Science Foundation [NSEC EEC-0914790]
Mantle-cell lymphoma (MCL) remains incurable despite numerous therapeutic advances. OSU-2S, a novel nonimmunosuppressive FTY720 (Fingolimod) derivative, exhibits potent cytotoxicity in MCL cell lines and primary cells. OSU-2S increased the surface expression of CD74, a therapeutic antibody target in MCL cells. OSU-2S, in combination with anti-CD74 antibody milatuzumab, enhanced cytotoxicity in MCL. Moreover, MCL tumor antigen receptor tyrosine kinase-like orphan receptor 1 (ROR1) targeted immunonanoparticle-carrying OSU-2S (2A2-OSU-2S-ILP)-mediated selective cytotoxicity of MCL in vitro, as well as activity in a xenografted mouse model of MCL in vivo. The newly developed OSU-2S delivery using ROR1-directed immunonanoparticles provide selective targeting of OSU-2S to MCL and other ROR1(+) malignancies, sparing normal B cells. Published by Elsevier Inc. on behalf of ISEH - International Society for Experimental Hematology.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据